ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 408

Frequency of Concomitant Non-aminoacyl-transfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome

Alexis Katz1, Soumya Chatterjee 2 and Yuxuan Jin 3, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, 3Quantitative Health Science, Cleveland Clinic, Cleveland, OH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: polymyositis/dermatomyositis (PM/DM) and interstitial lung disease

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Muscle Biology, Myositis & Myopathies Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Antisynthetase syndrome (ASSD) is an autoimmune disease with features including interstitial lung disease (ILD), myositis, inflammatory arthritis, Raynaud phenomenon, and mechanic’s hands.¹ Eight aminoacyl-transfer-RNA (tRNA) synthetase autoantibodies (Ab) have been described so far: Jo-1, PL-7, PL-12, EJ, OJ, YRS, KS, and Zo.¹ Sometimes, additional autoantibodies associated with other autoimmune rheumatologic disorders can be detected in patients with ASSD including ANA, anti-U1-RNP, anti-Sm, anti-ds-DNA, rheumatoid factor (RF), and anti-CCP.2,3,4 In ASSD, the coexistence of these autoantibodies may increase the prevalence of Raynaud phenomenon, dermatomyositis, and deforming arthropathy.2,3,4 Also, copresence of anti-SSA/Ro antibody in ASSD has been variably correlated with more severe interstitial lung disease.2,4,5 We completed a subset analysis evaluating the presence of other (non-tRNA synthetase) antibodies in patients with ASSD.

Methods: We obtained clinical data by retrospective review of electronic medical records from 2004 – 2017. The diagnosis of ASSD was confirmed by a rheumatologist, based on clinical phenotype and presence of one of the following autoantibodies: Jo-1, PL-7, PL-12, EJ, or OJ. Additional autoantibody positivity was determined by positive or negative values. Categorical variables were summarized using frequencies and percentages, and were compared using Pearson’s chi-square tests or Fisher’s exact tests. For all measures, a p-value of < 0.05 was considered significant.

Results: A total of 88 ASSD patients met criteria for inclusion in this study. The mean age was 57 years; 64% were female. The largest subset of patients was positive for Jo-1 Ab (N = 62). A positive ANA was noted in 63/88 patients (71.6%). ANA was more frequently positive in Jo-1 (87.1%) than those with ‘non-Jo-1 ASSD antibody’ (34.6%, p< .001) and PL-12 groups (23.1%, p< 0.001). RF was positive more frequently in PL-12 positive patients 5/13 (38.5%) than both in Jo-1 (11.3%, p=0.015) or ‘Non-PL-12 ASSD antibody’ groups (10.7%, p=0.009). Only 2/15 RF positive patients had radiographic evidence of deforming arthropathy, one of whom was also anti-CCP antibody positive and had erosions. No statistical comparisons were made for PL-7, EJ, and OJ antibodies due to small sample sizes.

Conclusion: Concomitant non-tRNA synthetase antibodies are common in patients with ASSD. Eighty five percent of our ASSD patients had at least one additional non-tRNA synthetase autoantibody, and almost 30% had at least three such additional autoantibodies, the most common ones being ANA, SSA, and RF. The impact of these autoantibodies on the phenotype and prognosis of ASSD patients remains unclear, and additional research is needed in this field.

 

  1. Katzap et al. Curr Rheumatol Rep, 13: 175.
  2. M. Fritzler et al. Journal of Rheumatology, 45 (3) 444-445.
  3. Cavagna L et al. Medicine (Baltimore); 94(32):e1144.
  4. Hervier et al. Curr Rheumatol Rep, 15: 349.
  5. R. La Corte, et al. Autoimmunity, 39:3, 249-253.


Table 1 updated


Table 2 updated


Table 3 updated


Disclosure: A. Katz, None; S. Chatterjee, None; Y. Jin, None.

To cite this abstract in AMA style:

Katz A, Chatterjee S, Jin Y. Frequency of Concomitant Non-aminoacyl-transfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/frequency-of-concomitant-non-aminoacyl-transfer-rna-synthetase-autoantibodies-in-patients-with-antisynthetase-syndrome/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-of-concomitant-non-aminoacyl-transfer-rna-synthetase-autoantibodies-in-patients-with-antisynthetase-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.